Search Results
Oct 23, 2025, 08:00 ET Ginkgo Bioworks in Partnership with STRM.BIO and University of British Columbia in Project to Develop In Vivo CAR Therapies Under ARPA-H's EMBODY Program
underscores Ginkgo's commitment to advancing RNA engineering and establishing itself as a credible partner in RNA cargo design for therapeutics companies. By participating in this groundbreaking program, Ginkgo plans to further develop and demonstrate its capabilities in RNA engineering and in vivo therapeutic
More news about: Ginkgo Bioworks
Oct 23, 2025, 08:00 ET Vial Initiates Phase 1 Trial of VIAL-INHBE, an INHBE (Activin E) siRNA for the Treatment of Obesity
including General Catalyst, Buckley Ventures, and Byers Capital. Vial is focused on advancing a pipeline of potentially best-in-class biologics and RNA therapeutics across areas of unmet medical need. Founded in 2020, Vial is a multidisciplinary team across R&D, Clinical Development, Clinical Operations,
More news about: Vial
Oct 22, 2025, 15:46 ET Pivot Bio CEO Chris Abbott Featured at the World Food Prize Foundation's 2025 Norman E. Borlaug International Dialogue
from nearly 400 applicants across 65 countries, these startups represent transformative, scalable ideas with the potential to reshape agriculture—from RNA-based crop protection to microbiome-powered soil solutions and AI-driven livestock care. The finalists will pitch their ventures
More news about: Pivot Bio, Inc
Oct 22, 2025, 12:00 ET Accent Therapeutics Presents New Preclinical Data on Lead Clinical Programs ATX-295 and ATX-559 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
About ATX-559 ATX-559 is a first-in-class potent and selective inhibitor of DHX9, a DNA/RNA helicase that plays a critical role in tumors with high levels of replication stress. Such tumors include those with BRCA loss of function (breast, ovarian),
More news about: Accent Therapeutics
Oct 22, 2025, 08:30 ET Co-Diagnostics Executive Leadership Team to Attend Global Health Exhibition 2025 in Riyadh, Saudi Arabia
diagnostics technologies. The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Oct 22, 2025, 07:00 ET Basking Biosciences Doses First Patients in Part B of Phase 2 Stroke Trial, Unlocks $27.5 Million Financing Tranche, and Appoints Julia C. Owens, Ph.D. as Chief Executive Officer
RAISE trial of BB-031. BB-031 is an investigational RNA aptamer targeting von Willebrand Factor (vWF), a key mediator of clot formation and stabilization. By promoting clot dissolution and restoring blood
More news about: Basking Biosciences Inc.
Oct 20, 2025, 11:00 ET Plug and Play Lifetech Announces Inaugural Batch of 12 Innovative Startups in Indianapolis
biotech developing a disruptive RNA delivery platform technology, "OmniSomes." This proprietary technology is highly differentiated, utilizing bioengineered Mesenchymal Stem cell-derived extracellular vesicles (EVs) as novel non-viral vectors for highly efficient RNA delivery, which uniquely confers
More news about: Plug and Play
Oct 20, 2025, 09:35 ET New NYC 'Liver ICU' Lab Transforming Liver Disease Treatments
Ochre Bio is a biotechnology company developing novel RNA medicines for under-treated chronic liver diseases. Its proprietary discovery platform combines machine learning and big human datasets, with in-house RNA chemistry, and testing in live human donor livers. Ochre Bio is headquartered
More news about: Ochre Bio
Oct 20, 2025, 09:00 ET Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies
More news about: Oncolytics Biotech® Inc.
Oct 20, 2025, 07:43 ET Exploring the Next Era of Cell & Gene Therapy with Nobel Laureate in London
in Molecular Medicine, co-director of the RNA Therapeutics Institute at the University of Massachusetts Medical School, is best known for his co-discovery of RNA interference (RNAi), a breakthrough that transformed genetic research and paved the way for RNA-based medicines. On the topic of "RNAi:
More news about: GenScript Biotech Corporation
Oct 19, 2025, 10:49 ET iOncologi Secures Foundational U.S. Patent as Landmark Studies Link COVID19 mRNA Vaccines to Improved Survival with Cancer Immunotherapy
-- iOncologi, Inc., a biotechnology company developing next-generation RNA-based cancer immunotherapies, today announced that the United States Patent and Trademark Office (USPTO) has granted a U.S. patent for a novel method using RNA-based formulations to enhance tumor responsiveness to immune checkpoint
More news about: iOncologi, Inc.
Oct 18, 2025, 13:38 ET HKUST Holds Congregation 2025 Conferring Honorary Doctorates on Five Distinguished Leaders
Kornberg followed in his father's footsteps to make significant contributions to molecular biology. His discovery of the nucleosome and detailed mapping of RNA polymerase II's function have revolutionized our understanding of genetic information processing. A member of the US National Academy of Sciences and
More news about: The Hong Kong University of Science and Technology
Oct 18, 2025, 13:27 ET HKUST Holds Congregation 2025 Conferring Honorary Doctorates on Five Distinguished Leaders
Kornberg followed in his father's footsteps to make significant contributions to molecular biology. His discovery of the nucleosome and detailed mapping of RNA polymerase II's function have revolutionized our understanding of genetic information processing. A member of the US National Academy of Sciences and
More news about: The Hong Kong University of Science and Technology
Oct 17, 2025, 10:37 ET Wobble Genomics Presents Latest Data at ESMO: establishing the robustness of an enhanced liquid biopsy platform for sensitive detection of low-abundance RNA
ultra-sensitive cell-free RNA (cfRNA) liquid biopsy diagnostic platform, today announced the presentation of new data at the European Society for Medical Oncology (ESMO) 2025 Congress. The study establishes the feasibility and analytical robustness of a novel long-read RNA sequencing assay
More news about: Wobble Genomics
Oct 17, 2025, 07:00 ET CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis
early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout
More news about: Insmed Incorporated
Oct 17, 2025, 04:38 ET Duchenne Muscular Dystrophy Therapeutics Market Surges Toward $6.6B by 2033 as Gene and RNA Therapies Redefine Treatment Paradigm | by DataM Intelligence
landscape with 45.1% market share, translating to approximately US $988 million in global revenue. This segment includes exon-skipping RNA therapeutics and gene replacement therapies that directly target the underlying genetic defect. Steroidal
More news about: DataM Intelligence 4 Market Research LLP
Oct 16, 2025, 09:30 ET Co-Diagnostics Announces Development of Proprietary Sample Prep Instrument for PoC Testing
diagnostics technologies. The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Oct 16, 2025, 09:00 ET Lexogen Launches miRVEL Profiling Small RNA-Seq Kit for Streamlined and Cost-Efficient sRNA Expression Analysis
Profiling Small RNA-Seq kit enables scientists to assess small RNA expression, investigate RNA interference studies, host-defense mechanisms, plant or agricultural sRNA research and many more applications. Small RNA profiling with miRVEL Small RNA-Seq is available in
More news about: LEXOGEN
Oct 16, 2025, 09:00 ET Lexogen Launches miRVEL Profiling Small RNA-Seq Kit for Streamlined and Cost-Efficient sRNA Expression Analysis
Profiling Small RNA-Seq kit enables scientists to assess small RNA expression, investigate RNA interference studies, host-defense mechanisms, plant or agricultural sRNA research and many more applications. Small RNA profiling with miRVEL Small RNA-Seq is available in
More news about: LEXOGEN
Oct 16, 2025, 09:00 ET Avidity Biosciences to Participate in Upcoming Investor Conference
DIEGO, Oct. 16, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate
More news about: Avidity Biosciences, Inc.
Oct 16, 2025, 08:00 ET Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston
Alzheimer's disease, and Parkinson's disease. The Company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. Klotho is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical
More news about: Klotho Neurosciences, Inc.
Oct 16, 2025, 07:00 ET Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025
early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout
More news about: Insmed Incorporated
Oct 15, 2025, 10:00 ET Nikon Small World Honors 51st Annual Photomicrography Competition
Distinction Bilal AkhtarInstitute of Molecular BiologyNeuroscience-RNA BiologyMainz, Rheinland-Pfalz, Germany14-day-old mouse neuronal co-culture with astrocytesConfocal40X (Objective
More news about: Nikon Instruments Inc.
Oct 15, 2025, 08:30 ET Clariane & ALCEDIAG present real-world data confirming the high acceptability of the myEDIT-B test in routine care at the European Congress of Neuropsychopharmacology (ECNP)
PARIS, Oct. 15, 2025 /PRNewswire/ -- Based on RNA editing and artificial intelligence, the myEDIT-B test reflects an emerging focus on precision psychiatry, providing a biological tool that complements
More news about: Alcediag
Oct 15, 2025, 07:00 ET Plasmidsaurus Launches Ultrafast RNA-Seq Service, Transforming Gene Expression Analysis with Unprecedented Speed, Affordability, and Convenience
Plasmidsaurus RNA-Seq delivers transformative advantages in RNA expression profiling: Unmatched speed: From crude cell preps to fully analyzed data in as fast as 3 days, vs. weeks to months for other RNA-Seq services
More news about: Plasmidsaurus